Patients with MECP2 gain-of-function mutations showed increased oxidative stress marker levels (plasma non-protein bound iron, intraerythrocyte non-protein bound iron, F 2 -isoprostanes, and F 4 -neuroprostanes), as compared to healthy controls (P ≤ 0.05).
Source: wiktionary